D89.810 Acute graft-versus-host disease

Name of the Condition

• Acute graft-versus-host disease

Summary

Acute graft-versus-host disease (aGVHD) is an immune-mediated complication that occurs when transplanted immune cells (graft) attack the recipient’s tissues (host). It typically arises within the first 100 days after allogeneic hematopoietic stem cell transplantation but can also occur in other settings, such as blood product transfusions. The condition commonly affects the skin, gastrointestinal tract, and liver, with clinical manifestations ranging from mild to severe. Early recognition and management are critical to reduce morbidity and mortality.

Causes

aGVHD is caused by donor immune cells recognizing the recipient’s tissues as foreign and mounting an immune response. In allogeneic transplantation, this occurs when the graft contains functional T cells that react against the host’s histocompatibility antigens. The risk increases with greater HLA mismatch between donor and recipient. Non-transplant-related aGVHD may occur after transfusions in immunocompromised patients, where donor lymphocytes engraft and attack the host.

Risk Factors

• Allogeneic hematopoietic stem cell transplantation
• HLA mismatch between donor and recipient
• Older age of the recipient
• Female donors for male recipients (due to prior pregnancies)
• Intensity of conditioning regimens
• Use of peripheral blood stem cells (vs. bone marrow)
• Prior episodes of acute GVHD

Symptoms

• Skin: Rash, erythema, or desquamation (often starting on palms/soles)
• Gastrointestinal tract: Nausea, vomiting, diarrhea, abdominal pain
• Liver: Elevated bilirubin, jaundice, or hepatomegaly
• Other: Fever, fatigue, or weight loss

Diagnosis

Diagnosis is based on clinical presentation, timing relative to transplantation, and histopathological confirmation. Skin biopsies may show interface dermatitis, while gastrointestinal biopsies can reveal crypt apoptosis or mucosal inflammation. Liver involvement is assessed via elevated transaminases and bilirubin, with biopsy showing bile duct damage or endotheliitis. Staging and grading systems (e.g., Glucksberg criteria) help quantify severity.

Treatment Options

• Immunosuppressive therapy: Corticosteroids (first-line), calcineurin inhibitors, or mycophenolate mofetil
• Supportive care: Fluid/electrolyte management, infection prophylaxis, and nutritional support
• Advanced therapies: Extracorporeal photopheresis or monoclonal antibodies (e.g., anti-IL-2 receptor) for refractory cases

Prognosis and Follow-Up

Prognosis depends on the severity of organ involvement and response to treatment. Mild cases may resolve with minimal intervention, while severe cases can lead to organ failure or death. Long-term follow-up is essential to monitor for chronic GVHD, infections, or secondary malignancies. Regular assessments of organ function and immune status are recommended.

Complications

• Organ failure (e.g., hepatic, gastrointestinal)
• Infections due to immunosuppression
• Chronic GVHD (if acute progresses)
• Metabolic disturbances (e.g., electrolyte imbalances)
• Reduced quality of life

Lifestyle & Prevention

• Pre-transplant: Optimize donor-recipient HLA matching and use reduced-intensity conditioning when possible
• Post-transplant: Adhere to immunosuppressive regimens and avoid exposure to infections
• Monitoring: Report new or worsening symptoms (e.g., rash, diarrhea) promptly to healthcare providers

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden onset of rash, severe diarrhea, or jaundice
• Persistent fever or signs of infection
• Unexplained weight loss or fatigue
• Worsening organ-specific symptoms (e.g., abdominal pain, dark urine)

Tips for Medical Coders

Document the timing of symptom onset relative to transplantation, as acute GVHD is defined by occurrence within 100 days. Specify organ systems involved (e.g., skin, gastrointestinal, liver) and any histopathological findings to support the diagnosis. Ensure documentation aligns with clinical staging/grading systems (e.g., Glucksberg) for accurate coding. Note any treatments initiated, as this may impact code assignment.